These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11818201)

  • 41. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
    Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
    J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
    Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
    Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
    Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
    Scarfone G
    Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).
    Lorusso V; Galetta D; Giotta F; Rinaldi A; Romito S; Brunetti C; Silvestris N; Colucci G
    Anticancer Res; 2006; 26(3B):2259-63. PubMed ID: 16821598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
    Lotz JP; Pautier P; Selle F; Viens P; Fabbro M; Lokiec F; Viret F; Gligorov J; Gosse B; Provent S; Ribrag V; Micléa JM; Dosquet C; Goetschel A; Cailliot C; Lefèvre G; Genève J; Lhommé C;
    Bone Marrow Transplant; 2006 Apr; 37(7):669-75. PubMed ID: 16501591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
    Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
    J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.
    Vecchione F; Fruscio R; Dell'Anna T; Garbi A; Garcia Parra R; Corso S; Lissoni AA
    Int J Gynecol Cancer; 2007; 17(2):367-72. PubMed ID: 17362314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
    Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.
    Fischer L; Thiel E; Klasen HA; Kirchen H; Jahnke K; Korfel A
    Neurology; 2004 May; 62(10):1885-7. PubMed ID: 15159503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
    Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
    Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
    Penson RT; Supko JG; Seiden MV; Fuller AF; Berkowitz RS; Goodman A; Campos SM; MacNeill KM; Cook S; Matulonis UA
    Cancer; 2001 Sep; 92(5):1156-67. PubMed ID: 11571729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.